【摘要】 目的:探讨超声造影(CEUS)联合血清潜在转化生长因子β结合蛋白2(LTBP2)、过氧化物酶6(PRDX6)对早期肝癌的诊断价值。方法:连续纳入2021年4月至2024年4月收治的157例肝癌患者(肝癌组)及157例良性肝部结节患者(良性组)为研究对象，采用酶联免疫吸附分析(ELISA)检测两组患者血清LTBP2、PRDX6水平；采用Pearson法分析LTBP2、PRDX6与CEUS参数的相关性；采用多因素Logistic分析肝癌患者的影响因素；采用受试者工作特征(ROC)曲线评估CEUS联合LTBP2、PRDX6对早期肝癌患者的诊断价值。结果:肝癌组在病灶不规则形态、边界特征不清晰、血供丰富、CEUS门脉期及延迟期等或低增强的患者占比显著高于良性组(P<0.05)。肝癌组峰值强度(PI)、平均通过时间(MTT)、LTBP2、PRDX6水平分别为(45.42±5.12)dB、(55.34±7.25)s、(11.42±3.15)ng/ml、(185.94±35.62)U/L,均高于良性组的(38.67±4.68)dB、(46.29±6.57)s、(9.13±2.21)ng/ml、(157.86±30.47)U/L,肝癌组达峰时间(TTP)为(22.37±6.58)s,低于良性组的(31.58±5.63)s(P<0.05)。LTBP2、PRDX6水平与TTP呈显著负相关，与PI和MTT呈显著正相关(P<0.05)。LTBP2、PRDX6为肝癌的危险因素。TTP、PI、MTT、LTBP2和PRDX6水平五者联合诊断早期肝癌患者的AUC优于各自单独诊断(P<0.05)。结论:早期肝癌患者血清LTBP2、PRDX6水平上调，CEUS联合血清LTBP2、PRDX6对早期肝癌患者的诊断价值较高。更多还原

【Abstract】 Objective:To explore the diagnostic value of contrast-enhanced ultrasound(CEUS) combined with serum latent transforming growth factor beta binding protein 2(LTBP2) and peroxiredoxin-6(PRDX6) for early liver cancer. Methods:From April 2021 to April 2024, 157 patients with liver cancer and 157 patients with benign liver nodules who visited our hospital were continuously included as the study subjects, and were included in the liver cancer group and benign group, respectively. ELISA method was applied to detect the serum LTBP2 and PRDX6 in liver cancer patients and benign group. Pearson method was applied to analyze the correlation between LTBP2, PRDX6, and CEUS parameters. Multivariate logistic method was applied to analyze the influencing factors of liver cancer patients. ROC curve was applied to evaluate the diagnostic value of CEUS combined with LTBP2 and PRDX6 in early liver cancer patients.Results:The proportions of lesion irregular morphology, unclear boundary, abundant blood supply, CEUS portal phase equal/low enhancement, and CEUS delayed phase equal/low enhancement in the liver cancer group were obviously higher than those in the benign group(P<0.05). The values of peak intensity(PI), mean transit time(MTT), and the levels of LTBP2 and PRDX6 in the live cancer group were(45.42±5.12) dB,(55.34±7.25) s,(11.42±3.15) ng/mL,(185.94±35.62) U/L, which were higher than those in benign group(38.67±4.68) dB,(46.29±6.57)s,(9.13±2.21) ng/mL,(157.86±30.47) U/L, and the value of time-to-peak(TTP) in the live cancer group[(22.37±6.58)s] was lower than that in benign group [(31.58±5.63) s](P<0.05). The LTBP2 and PRDX6 were obviously negatively correlated with TTP, and obviously positively correlated with PI and MTT(P<0.05). LTBP2 and PRDX6 were risk factors for liver cancer. The combination of TTP, PI, MTT, LTBP2, and PRDX6 had a better AUC in the diagnosis of early liver cancer patients than TTP, PI, MTT, LTBP2 and PRDX6 alone( P<0.05).Conclusion:Serum LTBP2 and PRDX6 are upregulated in early liver cancer patients. CEUS combined with serum LTBP2 and PRDX6 has a high diagnostic value for early liver cancer patients.更多还原